Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 11/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5033974 | 0.94 | DRD2 (0.48) | CACNA1HDRD2MAOAMAOBSIGMAR1 | |
| SCHEMBL5031510 | 0.89 | DRD2 (0.47) | CACNA1HDRD2SIGMAR1JAK2JAK1 | |
| SCHEMBL5034012 | 0.88 | CACNA1H (0.47) | CACNA1HDRD2JAK2JAK1TDP1 | |
| SCHEMBL16095384 | 0.85 | CACNA1H (0.49) | CACNA1HDRD2SIGMAR1JAK2JAK1 | |
| SCHEMBL1428134 | 0.84 | CACNA1H (0.51) | CACNA1HDRD2SIGMAR1JAK2JAK1 | |
| SCHEMBL5031368 | 0.83 | DRD2 (0.50) | CACNA1HDRD2SIGMAR1TDP1 | |
| SCHEMBL14708214 | 0.83 | CACNA1H (0.52) | CACNA1HDRD2SIGMAR1JAK2JAK1 | |
| SCHEMBL24817867 | 0.82 | SIGMAR1 (0.47) | CACNA1HDRD2SIGMAR1TDP1 | |
| SCHEMBL5031371 | 0.81 | DRD2 (0.48) | CACNA1HDRD2MAOAMAOBSIGMAR1 | |
| SCHEMBL14614740 | 0.81 | CACNA1H (0.53) | CACNA1HDRD2SIGMAR1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670474-A4 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080103148-A1 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-7317013-B2 | Cyclic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1670474-A2 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1656096-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | Parion Sciences, Inc. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | JOHNSON MICHAEL R (US) | 2005-04-28 | — | — | US | disclosed |
| WO-2005034847-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | PARION SCIENCES, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050059676-A1 | Cyclic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| WO-2005016879-A2 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103148-A1 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | HCN4, KCNH2, CACNA1B | CACNA1H 23/4885DRD2 1459/4885MAOA 1232/4885 |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | KCNN3, KCNN1, KCNN2 | CACNA1H 28/4885DRD2 2757/4885MAOA 1201/4885 |
| US-20050059676-A1 | Cyclic pyrazinoylguanidine sodium channel blockers | HCN4, KCNH2, CACNA1B | CACNA1H 23/4885DRD2 1459/4885MAOA 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.